Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000274

Purpose

The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Flupenthixol	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics

Resource links provided by NLM:

Drug Information available for: Haloperidol Flupenthixol decanoate Haloperidol decanoate Haloperidol lactate Flupenthixol

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Drug use
Psychiatric symptoms
Cocaine craving

Estimated Enrollment:	60
Study Start Date:	March 1997
Estimated Study Completion Date:	May 1999

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000274

Locations

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators

Principal Investigator:

Herbert Kleber, M.D.

New York State Psychiatric Institute

More Information

No publications provided

Study ID Numbers:	NIDA-09236-9, P50-09236-9
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000274 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Flupenthixol decanoate
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin
Antiemetics
Haloperidol
Pathologic Processes
Mental Disorders
Therapeutic Uses
Substance-Related Disorders

Cocaine-Related Disorders
Flupenthixol
Disease
Tranquilizing Agents
Gastrointestinal Agents
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions
Autonomic Agents
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 25, 2009